1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Malignancy: new trials by email Literature Review of Malignancy trials Research Report on Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 80 | 2017-09-01 | 2023-02-28 |
Neoplasms (1)
Ipilimumab (1) · Nivolumab (1) · Tetanus Toxoid (1)
Canada (1) · Spain (1) · Switzerland (1) · United States (1)
2017 (1)